Articles tagged with Glioblastomas
Researchers highlight the benefits of artificial intelligence in glioblastoma management, including improved diagnosis, treatment planning, and personalized therapy. AI-based models can analyze radiological images, predict tumor characteristics, and suggest effective treatments, promising to improve patient outcomes and survival rates.
Researchers developed a technique to measure brain tumors' mechanical force, distinguishing between tumors that push against the brain or invade surrounding tissue. This measurement can help clinicians inform patient strategies to alleviate symptoms and predict outcomes of chemotherapy and immunotherapy.
A new cytokine delivery platform reprograms the tumor microenvironment to enhance CAR-T cell function in preclinical brain cancer models. The strategy leads to a broader immune response that inhibits tumor growth and extends host survival, even in mice with only a fraction of cells expressing the CAR-targeted antigen.
Researchers create a potential treatment for glioblastoma, called MT-125, that makes malignant cells responsive to radiation and chemotherapy. The compound also blocks the cancer's ability to invade other tissue and has shown promise in animal studies.
Researchers at Florida Atlantic University have secured two key grants to investigate targeting the MBLAC1 gene as a new approach to treat glioblastoma, a very aggressive and fast-growing type of brain cancer. The project aims to advance innovative projects that could make a meaningful impact on cancer therapy.
The American Society for Radiation Oncology (ASTRO) has updated its guideline on radiation therapy for high-grade diffuse gliomas, the most common primary brain tumor in adults. The new guideline provides evidence-based recommendations for multidisciplinary treatment and addresses optimal radiation dosing, fractionation, and techniques.
A new molecule called the 'Fusion Superkine' has been created to target and kill glioblastoma cells while stimulating an immune response to prevent recurrence. The treatment, developed by VCU Massey Comprehensive Cancer Center researchers, uses a combination of immunotherapy and targeted delivery to overcome the blood-brain barrier and...
Researchers at the University of Missouri have developed a new imaging probe that can help surgeons accurately identify and remove aggressive brain tumors during operations. The tool, known as FA-ICG, uses near-infrared light to highlight tumor cells from within.
Researchers found that using Tumor Treating Fields therapy (TTFields) combined with immunotherapy (pembrolizumab) and chemotherapy (temozolomide) may extend survival for glioblastoma patients. TTFields disrupt tumor growth, attracting more immune cells to attack cancerous cells.
Researchers at Virginia Tech's Fralin Biomedical Research Institute are developing more precise treatments for pediatric brain cancer, specifically glioblastoma, by targeting cancer cells while sparing healthy tissue. The new therapies aim to deliver compounds more effectively to tumor sites using low-intensity focused ultrasound.
A phase I clinical trial demonstrates that dual-target CAR T cell therapy can reduce tumor size in nearly two-thirds of patients with recurrent glioblastoma, a notoriously aggressive brain cancer. The therapy also shows signs of long-term immune system activation and potential for extended tumor stability.
Researchers at Virginia Tech's Fralin Biomedical Research Institute developed a peptide therapy called JM2 that targets cancer cells' ability to renew and regrow. The treatment significantly slows tumor growth in animal models and disrupts the maintenance of treatment-resistant cancer cells.
Researchers have identified FAM111B as a promising candidate for glioma treatment. The study found that FAM111B overexpression enhances glioma malignancy through the PI3K/AKT pathway, providing a novel avenue for therapeutic intervention.
Researchers discovered a novel mechanism by which glioblastoma cells exploit astrocytes to evade immune responses. The study highlights an astrocyte-driven mechanism used by GBM to escape protective immune responses and could guide novel immunotherapies for the treatment of this aggressive brain cancer.
A new ultra-rapid genetic test has been developed to diagnose brain tumors in under two hours, cutting the current wait time of 6-8 weeks. The test uses Oxford Nanopore Technologies portable sequencing devices and achieves a 100% success rate.
A study by Mass General Brigham found that patients with glioblastoma who received gabapentin lived longer than those who didn't. The medication was shown to confer a four-month survival benefit, with patients on gabapentin surviving an average of 16 months compared to 12 months for those without the drug.
Researchers have developed a new compound, SHP1705, that selectively attacks glioblastoma stem cells by hijacked circadian clock proteins. The compound was found to be safe and well-tolerated in humans during a phase 1 clinical trial.
Researchers investigated the clinical outcomes of concurrent TTFields therapy with CRT in patients with newly diagnosed glioblastoma, finding no significant difference in survival outcomes compared to adjuvant therapy. The study also showed comparable safety profiles for both treatment groups.
Researchers at Ohio State University have identified new targeted therapies for treating small cell lung cancer, predicting melanoma spread, and reducing endometrial cancer risk. A 31-gene expression profile has been developed to identify patients at high risk of melanoma spread, allowing for closer monitoring and earlier treatment.
Researchers at Michigan Medicine have created nanodiscs that can target cholesterol levels in glioblastoma, starving cancer cells and increasing survival rates of treated mice. The combined treatment with radiation therapy was able to preserve normal brain structure and elicited an immunological memory.
Researchers have found that targeting PGM3 can help stop the growth of glioblastoma, a fast-growing brain tumor. By blocking this enzyme, tumors can be effectively suppressed.
Researchers found that combining imipridones with radiation therapy and temozolomide slowed glioblastoma growth and prolonged survival in mice. The treatment also boosted immune responses and suppressed MGMT protein expression, making it more effective.
A recent study reveals that high-mobility group nucleosomal-binding domain 2 (HMGN2) plays a crucial role in glioma progression and serves as a potential biomarker for predicting prognosis. HMGN2 regulates cell cycle progression by binding to histones, enhancing transcriptional activity of proliferation-related genes such as CDC20.
Researchers at UT Health San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation by targeting senescent cells with experimental 'senolytic' drugs. This approach shows promise in preventing tumor growth and improving patient survival.
Researchers analyzed trends in efficacy endpoints for glioblastoma phase II clinical trials, finding a shift towards using time-to-event measures like progression-free survival (PFS) and overall survival (OS). This trend reflects the complexity of GBM treatment evaluation and may indicate evolving clinical trial design.
Researchers identified the prion protein as a key player in the progression of glioblastoma, a type of brain tumor. The study found that blocking the production of this protein using genetic editing reduced the ability of tumor stem cells to proliferate and invade tissues.
Researchers found that suppressing ZNF638 triggers an antiviral immune response in glioblastoma patients, making them more susceptible to treatment. This finding offers a potential new treatment strategy for the disease, which has remained challenging despite recent advances in immunotherapy.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.
Researchers discover engineered TIMP molecules can block cancer cell migration and invasion, offering a targeted approach to treating GBM. The findings also suggest the potential for safe treatment with minimal side effects.
Researchers combine radiation with a plant-derived compound to combat glioblastoma, forcing cancer cells into a dormant state. The approach significantly slows tumor growth and improves survival in mice models, offering a potential new avenue for combating this deadly form of brain cancer.
Researchers at Dana-Farber Cancer Institute found that combining navtemadlin with DNA-damaging chemotherapy can increase efficacy in treating glioblastoma. Navtemadlin activates the p53 pathway, killing glioblastoma cells more effectively than other treatments.
Researchers have developed a new gene therapy that targets aggressive brain cancer, glioblastoma, with a precise delivery system. The treatment uses a novel virus to deliver a targeting drug to cancer cells, achieving cure rates of up to 90% in mouse models.
A recent study from Memorial Sloan Kettering Cancer Center sheds new light on the heterogeneity of GBM tumors and the role of cancer stem cells in tumor growth. The research identifies six distinct transcriptional states, each with its own unique gene signature, and provides guidance for future research to develop targeted therapies.
Researchers at UCSF have discovered a new type of stem cell in the young brain that can form cells found in tumors, shedding light on how adult brain cells grow and develop into deadly brain cancers. The study provides a comprehensive roadmap for understanding healthy brain development, which could lead to better treatments for conditi...
A study suggests targeting endocan, a protein produced by endothelial cells in blood vessels, could slow tumor growth and make glioblastoma more vulnerable to existing treatments. The discovery may lead to new strategies to combat glioblastoma, which has an average lifespan of just 12-15 months.
Researchers uncover Achilles' heel of TMZ chemotherapy resistance, revealing critical insights into mechanisms behind glioblastoma's inactivation of DNA repair pathways. The study sheds light on potential mechanisms of aging and offers new avenues for developing more effective therapies against this devastating cancer.
A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.
A new study shows targeted delivery of energy-disrupting gene therapy using nanoparticles shrinks glioblastoma brain tumors and aggressive breast cancer tumors in mice. The technology, mLumiOpto, induces light-activated electrical currents inside cells to disrupt mitochondria, leading to programmed cell death and DNA damage.
Glioblastoma brain tumors synchronize their growth with the daily release of steroid hormones like cortisol, according to new research. Blocking these signals slows tumor growth and disease progression in animal models.
Researchers used lab-grown organoids from glioblastoma tumors to model patient response to CAR T cell therapy. The organoids accurately reflected the treatment's effect on actual tumors, providing a promising tool for personalized medicine.
Scientists have created a living cell therapy that can navigate to specific organs using a
A new study from UCLA Health Jonsson Comprehensive Cancer Center introduces a combined genetic and functional profiling approach to predict how glioblastoma will respond to therapy. The approach helps identify new ways to target and treat the tumors more effectively, including using an experimental drug called ABBV-155.
MSK researchers have identified a compound that selectively kills glioblastoma cells while sparing healthy cells. They also developed a new method to study cancer evolution by introducing mutations in specific genes, allowing for the rapid regression of leukemia and understanding its behavior.
Scientists at WashU Medicine have successfully forced glioblastoma cells to display immune system targets, potentially making them vulnerable to immunotherapies. The strategy involves a combination of two FDA-approved epigenetic therapy drugs that induce the production of unusual proteins called neoantigens.
Glioblastoma is a deadly form of brain cancer affecting 500 Swedes annually. Researchers have identified 'foam cells' that aid tumour growth by releasing signal substances and promoting blood vessel formation.
A team of researchers at the University of Toronto has discovered two distinct subtypes of glioblastoma cancer stem cells, each with unique genetic vulnerabilities. By targeting these vulnerabilities, a more effective treatment approach may be developed, improving prognosis for patients with this lethal brain cancer.
Researchers found Edaravone inhibits growth of brain tumor stem cells and prolongs survival in mice with glioblastoma. The study suggests repurposing Edaravone as a potential treatment for this aggressive brain cancer.
Glioblastoma, the most malignant primary brain tumour, has an 18-month median survival rate despite treatment. New research from the University of Ottawa suggests a drug used to slow ALS progression may also suppress glioblastoma's self-renewing cancerous stem cells.
A recent clinical trial analysis found that patients with truly unmethylated MGMT promoter do not benefit from temozolomide treatment, challenging current treatment protocols. This study aims to transform the treatment landscape for older adults glioblastoma patients by identifying biomarkers for more personalized therapies.
Researchers evaluated the efficacy and safety of using Zika virus for treating CNS tumors, finding that it reduces cell viability, inhibits growth, and decreases Bcl2 expression, potentially enhancing chemotherapy and radiotherapy effects. This ultimately led to significant tumor remission and improved long-term survival through an enh...
A new study by Sylvester Comprehensive Cancer Center researchers shows that daily MRI imaging paired with radiation can monitor tumor changes in real-time. The technology has the potential to signal early warning signs of tumor growth, allowing for faster and more targeted treatment adaptations.
Researchers created an artificial blood vessel model using 3D bioprinting to test new therapies for glioblastoma. This device enables the creation of personalized disease models, potentially improving patient survival rates.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
Researchers have uncovered a critical mechanism by which mutant p53 protein converts other proteins into cancer-promoting agents, driving tumor growth. Heparin, a widely used anticoagulant, can inhibit the formation of these harmful aggregates, providing a potential therapeutic approach.
Researchers have successfully visualized and tracked specific cells in deep brain tissue, including along the corpus callosum's nerve fibre highway. This advancement could potentially lead to better diagnostic tools for glioblastoma, a deadly brain cancer.
New vaccines are being explored as a promising approach to treating glioblastoma, a highly lethal brain cancer with limited treatment options. These vaccines have been generally well-tolerated and have shown promise in improving survival rates for GBM patients.
A novel, automated device has been developed to diagnose glioblastoma in under an hour using a biochip that detects biomarkers. The device requires only 100 microliters of blood and costs less than $2 to manufacture.
A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.
Scientists used AI to identify genes that can convert brain cancer cells into immune cells, increasing survival chances by up to 75% in mouse models. The approach bypasses the blood-brain barrier, offering new hope for aggressive cancers.